Why did VOR's EPS stagnate in 2024?

Vor Biopharma's EPS stagnated in 2024 due to several factors:

1. **High Research and Development Costs**: As a biotechnology company, Vor Biopharma is likely to have high research and development costs, which can negatively impact its earnings. The company is currently prioritizing R&D over immediate profitability, as indicated by the negative EPS forecasts for the upcoming fiscal years.
2. **Investment in Clinical Trials and Programs**: The company has been actively investing in its clinical programs, including the development of VCAR33 and the trem-cel + Mylotarg combination. These investments are likely contributing to the negative EPS, as they require significant resources and funding.
3. **Financial Position**: Vor Biopharma's financial position is characterized by a strong current ratio of 4.69, indicating ample liquidity to fund initiatives. However, the company is also quickly burning through its cash reserves, which could be a concern.

In summary, Vor Biopharma's EPS stagnation in 2024 is likely a result of high R&D costs, investments in clinical trials and programs, and financial position.